The efficacy of chemokine C-X-C motif ligand 12 as a diagnostic marker for papillary thyroid carcinoma
- Alternative Title
- 갑상선암 진단에 있어서 CXCL12의 유용성
- Abstract
- The incidence of thyroid cancer is increasing worldwide, with the most dramatic growth being the up to 25% annual increase observed over the last 10 years in Korea. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer in Korea, and it is essential to develop methods for the accurate diagnosis of PTC to avoid unnecessary surgery. Chemokine C-X-C motif ligand 12 (CXCL12) has been reported to be associated with chemokine C-X-C motif receptor 4 (CXCR4) mediated activation of G-protein-coupled signaling molecules in various cancers. We aimed to study the efficacy of CXCL12 for the diagnosis of PTC. We prospectively collected 58 PTC samples from 2013 to 2015 and obtained 31 benign thyroid disease samples from the Korea Biobank of Jeju National University Hospital. Immunohistochemical and immunocytochemical staining for CXCL12 and B-type Raf kinase (BRAF) V600E mutant protein were performed on fine-needle aspiration (FNA) and tissue microarray (TMA). A BRAF V600E gene mutation study was also performed. The mean age of the subjects was 49.1±1.4 years and 88.5% were wemen. CXCL12 and BRAF were positive in 6.4% and 19.4% of cases of benign disease and 98.3% and 93.1% of PTCs, respectively. The sensitivity of CXCL12 was 93.1% in FNA and 98.3% in TMA, and that of BRAF was 62.1% in FNA and 93.1% in TMA. CXCL12 showed 90.3% specificity, 94.7% positive predictive value, 87.5% negative predictive value and 89.1% accuracy for diagnosis of PTC. Among the cases of atypia of undetermined significance (AUS), CXCL12 in FNA showed 100% sensitivity and 100% specificity compared with 62.5% sensitivity and 100% for BRAF. Strong CXCL12 expression (3+) was correlated with lymph node metastasis (p = 0.031), but not tumor size. In conclusion, CXCL12 in FNA and TMA may be an effective diagnostic marker for PTC and could facilitate its accurate diagnosis, especially in cases where the FNA is initially reported as AUS.
- Author(s)
- 이상아
- Issued Date
- 2017
- Awarded Date
- 2017. 2
- Type
- Dissertation
- URI
- http://dcoll.jejunu.ac.kr/jsp/common/DcLoOrgPer.jsp?sItemId=000000007978
- Alternative Author(s)
- Sang Ah Lee
- Department
- 대학원 의학과
- Advisor
- 맹영희
- Table Of Contents
- ABSTRACT 8
INTRODUCTION. 9
MATERIALS AND METHODS 13
1. Subjects 13
2. Protocol 13
3. Tissue Microassay (TMA) construction 13
4. Immunohistochemistry and Immunocytochemistry 14
5. DNA extraction 14
6. Detection of BRAF V600E mutation 15
7. Statistical analysis 15
RESULTS 17
1. The baseline characteristics of patients 17
2. The expression of CXCL12 and BRAF V600E mutant protein in specimens of benign disease and papillary thyroid carcinoma 18
3. The BRAF V600E gene mutation in thyroid specimens 23
4. The clinical efficacy for diagnosis of papillary thyroid carcinoma in specimens classified as atypia of undetermined significance 23
5. The correlation of CXCL12 and BRAF expression with tumor stage 25
DISCUSSION 27
REFERENCES 30
- Degree
- Doctor
- Publisher
- 제주대학교 일반대학원
- Citation
- 이상아. (2017). The efficacy of chemokine C-X-C motif ligand 12 as a diagnostic marker for papillary thyroid carcinoma
-
Appears in Collections:
- General Graduate School > Medicine
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.